Search results
Showing 16 to 30 of 30 results for diabetic retinopathy
Insertion of a subretinal prosthesis system for retinitis pigmentosa (HTG392)
Evidence-based recommendations on insertion of a subretinal prosthesis system for retinitis pigmentosa. This involves performing a vitrectomy and implanting a microchip underneath the macula using a transscleral, then subretinal approach.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.
View recommendations for HTG191Show all sections
Sections for HTG191
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Arteriovenous crossing sheathotomy for branch retinal vein occlusion (HTG211)
Evidence-based recommendations on arteriovenous crossing sheathotomy for branch retinal vein occlusion. This involves cutting the sheath around the vessels and physically separating them where they cross to improve blood flow through the vein.
View recommendations for HTG211Show all sections
Sections for HTG211
Evidence-based recommendations on retrobulbar irradiation for thyroid eye disease. This involves using radiation to target the tissue behind the eyeball and reduce inflammation.
View recommendations for HTG94Show all sections
Sections for HTG94
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Discontinued Reference number: GID-TAG386
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes